3 citations
,
July 2022 in “The Journal of Dermatology” COVID-19 infection can cause new hair loss conditions or worsen existing skin diseases, with hair loss being the most common issue.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
1 citations
,
February 2024 in “Pharmaceutics” Nanovesicles improve drug delivery through the skin, offering better treatment outcomes and fewer side effects.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
June 2022 in “Journal of Paediatrics and Child Health” Young adults who had liver disease as children often experience significant health problems and frequently need transplants.
1 citations
,
January 2022 in “Annals of Dermatology” Dutasteride is more effective than finasteride for long-term hair growth in men with androgenic alopecia.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
February 2026 in “Trials” The Exfoliate-Dissolve-Repair skincare approach may effectively treat keratosis pilaris and reduce the need for corticosteroids.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.